In 2011, Kiskowski et al elegantly demonstrated, for the first time, that mixed populations of transforming growth factor‐beta (TGF‐β) responsive and TGF‐β nonresponsive stromal cells can drive prostate adenocarcinoma, whereas alone these stromal components only support benign or precancerous lesions [46]. The gene discussed is TGFB1; the disease is prostate adenocarcinoma.